Dr. Gomella Appointed to Editorial Council for Urology Times and Mid Atlantic Representative for Scociety for Urology Chairperson and Program Directors

Dr. Leonard Gomella, M.D., F.A.C.S., the Bernard W. Godwin, Jr. Professor of Prostate Cancer, associate director for Clinical Affairs at the Kimmel Cancer Center (KCC) at Jefferson, and Chair of the Department of Urology at Jefferson Medical College of Thomas Jefferson University, has been appointed as a member of the Urology Times Editorial Council. He …


Marker Identifies Breast Cancer Patients Likely to Respond to Tamoxifen

ER positive breast cancer patients whose tumors have active protein Stat5 have increased likelihood of responding to anti-estrogen therapy PHILADELPHIA—Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy. The research appears …


Jefferson Researchers Unlock Key to Personalized Cancer Medicine Using Tumor Metabolism

Identifying gene mutations in cancer patients to predict clinical outcome has been the cornerstone of cancer research for nearly three decades, but now researchers at the Kimmel Cancer Center at Jefferson have invented a new approach that instead links cancer cell metabolism with poor clinical outcome. This approach can now be applied to virtually any …


Radiation Oncology Announcements and Appointments

New faculty: Thomas Jefferson University welcomes two new, seasoned clinicians and researchers to its Department of Radiation Oncology: Nicole Simone, M.D., from the National Institutes of Health’s National Cancer Institute (NCI) and Bo Lu, M.D., Ph.D, from Vanderbilt University. Dr. Simone is a board-certified Radiation Oncologist who has treated mostly patients with breast and head …


“Longevity” Protein SIRT1 May Ward Off Precursor to Prostate Cancer

Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the “longevity” protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia (PIN). “Prostate cancer is one of the malignancies that has a …


Researchers Say Stress Fuels Cancer Growth, Provide Genetic Evidence That Antioxidants Can Help Treat It

Researchers from Jefferson’s Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stress—a culprit in driving tumor growth. For the first time, the researchers show that loss of the …


Dr. Eric Wickstrom Elected AAAS Fellow

Eric Wickstrom, Ph.D., of Jefferson Medical College, Kimmel Cancer Center, recognized for creating new methods to see cancer gene activity from outside the body Exemplary work in genetic imaging and therapy have earned  Eric Wickstrom, Ph.D., a Professor of Biochemistry & Molecular Biology at Jefferson Medical College of Thomas Jefferson University and member of the …


Loss of the retinoblastoma tumor suppressor pushes prostate cancer into lethal stage, say Kimmel Cancer Center researchers

Their study, the first to uncover a new role for this powerful gene, may lead to clinical “barcoding” of a patient’s prostate cancer to help direct therapy (PHILADELPHIA) – The retinoblastoma tumor suppressor gene (Rb), long thought to protect cells against cancer development, appears to play a very different role in prostate cancer, say scientists …


CancerCare Awards Dr. Edith Mitchell With Physician Of The Year Award

The national nonprofit CancerCare presented its Physician of the Year Awards to two nationally recognized leaders in oncology and cancer patient care during its annual “Tribute to Our Friends” awards ceremony, held on September 30 at CancerCare’s national office in New York City. On of the “Physician of the Year Awards” was presented top Dr. …


“How & Why” Cancer Cells Eat Us Alive

Four key studies now propose a new theory about how cancer cells grow and survive, allowing researchers to design better diagnostics and therapies to target high-risk cancer patients.  These studies were conducted by a large team of researchers at Thomas Jefferson University’s Kimmel Cancer Center.


Reception to Celebrate Dr. Dicker’s Appointment as Chairman

A reception to celebrate Dr. Adam Dicker’s appointment as Chairman of Radiation Oncology was held in the Hamilton Building on Wednesday May 26, 2010. For more about Dr. Dicker’s appointment please go here


Scientists Find Protein Spurs Spread of Prostate Cancer

Researchers from the Kimmel Cancer Center at Jefferson have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis. Their study, published in the online edition of Endocrine-Related Cancer, demonstrates in both laboratory and animal models that nuclear Stat5 over-expression leads to a deadly …


Small RNA Molecules Block Breast Cancer from Spreading via Newly Identified Secreted Factor

The role of genes and proteins in cancer control is well known, but now researchers at Jefferson’s Kimmel Cancer Center have found a cluster of microRNA (miRNA) molecules that act to suppress the invasive spread of breast cancer. MiRNAs are non-coding small RNA molecules found in wide areas of the genome that, either singly or …


Clue to Switch of Bladder Cancer from Locally Contained to Invasive Found by Jefferson Scientists

Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive – and deadly. “We have found that IGF-IR is a critical regulator of motility and invasion of bladder cancer cells, …


Dr. Leonard G. Gomella Studies the Effect of Dutasteride on the Risk of Prostate Cancer

Dr. Leonard G. Gomella and colleagues conducted a landmark international randomized, double-blind, placebo-controlled, parallel-group multi-center clinical trial to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Over the course of the 4-year study period, dutasteride reduced the risk of …

Page 5 of 5